Results 61 to 70 of about 8,546 (232)

Effects on Serum Protein Levels From One Bout of High Intensity Interval Training in Individuals With Axial Spondyloarthritis and Controls

Immunity, Inflammation and Disease, Volume 13, Issue 12, December 2025.
ABSTRACT Background Axial spondyloarthritis (axSpA) is a chronic inflammatory disease primarily affecting the axial skeleton causing pain, inflammation, and stiffness. Individuals with axSpA are at greater risk of developing cardiovascular disease, which can be counteracted by physical activity. High‐intensity interval training (HIIT) has been shown to
Åsa Andersson, M. Charlotte Olsson, Anna Torell, Elisabeth Mogard, Emma Haglund   +4 more
wiley   +1 more source

Association Study of IL-12B Polymorphisms Susceptibility with Ankylosing Spondylitis in Mainland Han Population.

PLoS ONE, 2015
ObjectiveThis study aims to determine whether the genetic polymorphisms of IL-12B gene is a susceptibility factor to Ankylosing spondylitis (AS) in mainland Han Chinese population.MethodEight single-nucleotide polymorphisms (SNPs) (rs10045431, rs11167764,
Li Zhang, Dazhi Fan, Li Liu, Ting Yang, Ning Ding, Yanting Hu, Guoqi Cai, Li Wang, Lihong Xin, Qing Xia, Xiaona Li, Shengqian Xu, Jianhua Xu, Xiao Yang, Yanfeng Zou, Faming Pan   +15 more
doaj   +1 more source

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study [PDF]

, 2017
AIM To report adalimumab (Ada) efficacy on articulargastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES).
Benfaremo, D., Bolognini, L., Ciccia, F., Ciferri, M., Farinelli, A., Gabrielli, A., Luchetti, M., Mosca, P., Rossini, M., Triolo, G.   +9 more
core   +1 more source

Core Set of Responsive and Discriminatory Measures for Use in Pragmatic Trials of Youth With Axial Juvenile Spondyloarthritis

Arthritis Care &Research, Volume 77, Issue 10, Page 1229-1239, October 2025.
Objective The objective of this study was to determine a core set of measures for youth with juvenile spondyloarthritis and axial disease (axJSpA), using the juvenile arthritis working group Outcome Measures in Rheumatology framework. Methods This was a prospective multicenter study of youth with axJSpA.
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force [PDF]

, 2013
Background: Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA). Objective: To define the treatment
Baraliakos, Xenofon, Betteridge, Neil, Braun, Jürgen, Burgos-Vargas, Ruben, Collantes-Estevez, Eduardo, de Wit, Martinus, Deodhar, Atul, Dougados, Maxime, Elewaut, Dirk, Emery, Paul, FitzGerald, Oliver, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kavanaugh, Arthur, Kvien, Tore K, Landewé, Robert, Luger, Thomas, Maccarone, Mara, Mease, Philip, Olivieri, Ignazio, Redlich, Kurt, Reveille, John, Ritchlin, Christopher, Rudwaleit, Martin, Schoels, Monika, Sieper, Joachim, Smolen, Josef S, Van den Bosch, Filip, van der Heijde, Désirée, Wei, James Cheng-Chung, Winthrop, Kevin   +31 more
core   +2 more sources

Comparative Effectiveness and Safety of Adalimumab, Secukinumab, and Upadacitinib in Psoriatic Arthritis: A Prospective Cohort Study Based on PARWCH Cohort

The Journal of Dermatology, Volume 52, Issue 10, Page 1527-1535, October 2025.
ABSTRACT Psoriatic arthritis (PsA) is a chronic inflammatory disease, with prevalence among psoriasis patients ranging from 6% to 42% across populations. Although targeted therapies such as adalimumab (ADA), secukinumab (SEC), and upadacitinib (UPA) have demonstrated efficacy in randomized controlled trials, real‐world head‐to‐head comparisons remain ...
Yiyi Wang, Jingya Gao, Furong Li, Luyuan Li, Yue Xiao, Hongxiang Hu, Xiya Peng, Min Yang, Dan Hao, Wei Yan, Dengmei Xia, Wei Li   +11 more
wiley   +1 more source

BioRePortAP, an electronic clinical record coupled with a database : an example of its use in a single [PDF]

, 2010
Aims: To evaluate the efficacy and safety of the treatment of psoriatic arthritis (PsA) patients with tumor necrosis factor (TNF) antagonists in the Rheumatology Department of Hospital de Santa Maria using the BioRePortAP.
Campanilho-Marques, R., Canhao, Helena, Costa, M., Fonseca, João Eurico, Martins, F., Pereira da Silva, José A., Polido-Pereira, J., Ramos, F., Rodrigues, A., Saavedra, M. J.   +9 more
core  

Az interdiszciplináris rehabilitáció hatása spondylitis ankylopoeticában szenvedő betegekben [PDF]

, 2016
Absztrakt Bevezetés: A légzőszervi manifesztációval kapcsolatos komplex pulmonalis vizsgálat spondylitis ankylopoeticában szenvedő betegekben hozzájárulhat a megfelelő rehabilitációs program ...
Hegedűs, Béla, Somfay, Attila, Varga, János   +2 more
core   +1 more source

B3GNT2, GPR35, PSMG1 Gene Polymorphisms Are Related With Susceptibility and Severity of Ankylosing Spondylitis in Chinese Han Population

Molecular Genetics &Genomic Medicine, Volume 13, Issue 8, August 2025.
B3GNT2, GPR35, and PSMG1genes are related to ankylosing spondylitis in the Chinese Han population. ABSTRACT Background Latest research on ankylosing spondylitis (AS) indicates a link between the B3GNT2, PSMG1 genes and susceptibility to AS among western populations.
Zijian Lian, Bin Zhao, Wei Luo, Jun Liu, Jing Wang, Wei Chai, Yan Wang, Songqing Ye, Xinlong Ma   +8 more
wiley   +1 more source

Changes in Descending Pain Modulation During Anti–Tumor Necrosis Factor Therapy: A Prospective Study in Rheumatoid Arthritis and Spondyloarthritis

Arthritis &Rheumatology, Volume 77, Issue 6, Page 658-663, June 2025.
Objective In rheumatoid arthritis (RA) and spondyloarthritis (SpA), managing persistent pain remains challenging. Little is known regarding impaired pain pathways in these patients and the impact of biologic disease‐modifying antirheumatic drugs (bDMARDs).
Anne‐Priscille Trouvin, Arielle Simunek, Joël Coste, Terkia Medkour, Alice Combier, Lucile Poiroux, François Vidal, Sandrine Carvès, Didier Bouhassira, Serge Perrot   +9 more
wiley   +1 more source